EUROPE
For any company , undergoing a major merger or acquisition can be disruptive , often challenging and in some cases , can even break apart a client or customer base . After all , if a leading conglomerate swallows up a smaller company , will that smaller company and its smaller operating model and attitudes continue to exist ?
This is the question facing Accord Healthcare , a subsidiary of Intas Pharmaceuticals , born out of the acquisition of Actavis UK and Ireland ltd in January 2017 . The goal of Accord ? To become the best supplier of generic medicines in the UK and Ireland .
Heading up the company ’ s supply chain operations is Brandon Turk , Director of EU Supply Operations . Brandon brings with him more than 20 years ’ experience operating in the supply chain space across a number of sectors , before joining Actavis back in 2015 .
In fact , it is this diversified experience across multiple sectors that allows Brando to steer this ambitious company towards that goal of being a leading European player .
“ I very much view supply chain as a toolset that you can take with you from company to company ,” he says . “ If you understand how things are made , you can apply that logic and best practice supply chain processes to pretty much any industry .”
Accord is very much a growing company and in the generic medicines space , this can present a challenge in trying to establish a solid footing in a crowded market . Prior to the merger , Actavis was already a leading supplier of generic pharmaceuticals in the UK , with a portfolio that supports more than 85 % of pharmacists dispensing needs . Intas Pharmaceuticals is among the top 10 Indian pharmaceutical companies and is the largest privately held pharmaceutical company in India .
With the coming together of two leading pharmaceutical players , where then does that leave Accord ? Is it an extension of what ’ s come before or is it a new entity altogether ?
“ It ’ s one of the fastest growing pharmaceutical companies in
www . supplychaindigital . com 37